CASI Pharmaceuticals Inc
CASI1.950USD
+0.660+51.16%
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
30.21MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über CASI Pharmaceuticals Inc Unternehmen
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Unternehmensinformationen
BörsenkürzelCASI
Name des UnternehmensCASI Pharmaceuticals Inc
IPO-datumAug 23, 2021
CEODr. Wei-Wu He, Ph.D.
Anzahl der mitarbeiter233
WertpapierartOrdinary Share
GeschäftsjahresendeAug 23
Addresse1701-1702, China Central Office Tower 1
StadtBEIJING
BörseNASDAQ Capital Market Consolidated
LandChina
Postleitzahl100025
Telefon861065618789
Websitehttps://www.casipharmaceuticals.com/
BörsenkürzelCASI
IPO-datumAug 23, 2021
CEODr. Wei-Wu He, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Wei-Wu He, Ph.D.
Dr. Wei-Wu He, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.52M
+11.33%
Mr. Xuebo Zeng
Mr. Xuebo Zeng
Independent Director
Independent Director
--
--
Dr. Y. Alexander Wu, Ph.D.
Dr. Y. Alexander Wu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Wei Gao
Ms. Wei Gao
General Counsel
General Counsel
--
--
Mr. Thomas Folinsbee
Mr. Thomas Folinsbee
Independent Director
Independent Director
--
--
Ms. Kun Qian
Ms. Kun Qian
Vice President, Global Controller
Vice President, Global Controller
--
--
Mr. Wei (Larry) Zhang, Ph.D.
Mr. Wei (Larry) Zhang, Ph.D.
Senior Vice President
Senior Vice President
--
--
Ms. Chunhua Wang
Ms. Chunhua Wang
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Rui Zhang
Mr. Rui Zhang
Investor Relations
Investor Relations
--
--
Mr. Huang Hai
Mr. Huang Hai
Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China
Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Wei-Wu He, Ph.D.
Dr. Wei-Wu He, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.52M
+11.33%
Mr. Xuebo Zeng
Mr. Xuebo Zeng
Independent Director
Independent Director
--
--
Dr. Y. Alexander Wu, Ph.D.
Dr. Y. Alexander Wu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Wei Gao
Ms. Wei Gao
General Counsel
General Counsel
--
--
Mr. Thomas Folinsbee
Mr. Thomas Folinsbee
Independent Director
Independent Director
--
--
Ms. Kun Qian
Ms. Kun Qian
Vice President, Global Controller
Vice President, Global Controller
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Jul 25
Aktualisiert: Fri, Jul 25
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
He (Wei-Wu)
22.69%
Panacea Venture Healthcare Fund I LP
13.23%
Foresite Capital Management, LLC
8.58%
Sparkle Byte Ltd
6.58%
VR Adviser, LLC
6.37%
Other
42.54%
Aktionäre
Aktionäre
Anteil
He (Wei-Wu)
22.69%
Panacea Venture Healthcare Fund I LP
13.23%
Foresite Capital Management, LLC
8.58%
Sparkle Byte Ltd
6.58%
VR Adviser, LLC
6.37%
Other
42.54%
Aktionärstypen
Aktionäre
Anteil
Corporation
25.68%
Individual Investor
22.70%
Venture Capital
12.28%
Private Equity
8.58%
Hedge Fund
1.62%
Investment Advisor
0.81%
Research Firm
0.21%
Investment Advisor/Hedge Fund
0.14%
Other
27.98%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
52
11.16M
72.02%
+1.11M
2025Q1
57
11.41M
73.67%
+1.54M
2024Q4
58
11.33M
84.52%
+2.13M
2024Q3
57
9.91M
73.95%
+2.26M
2024Q2
62
7.31M
54.55%
-1.23M
2024Q1
76
7.47M
55.75%
-860.83K
2023Q4
80
7.18M
53.75%
+54.06K
2023Q3
94
6.57M
49.20%
-572.41K
2023Q2
112
6.68M
49.99%
-822.50K
2023Q1
150
6.80M
50.47%
+209.73K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
He (Wei-Wu)
3.52M
22.69%
+357.64K
+11.33%
Jun 16, 2025
Panacea Venture Healthcare Fund I LP
1.32M
8.54%
+305.00K
+29.95%
Sep 30, 2024
Foresite Capital Management, LLC
1.33M
8.58%
--
--
Mar 31, 2025
Sparkle Byte Ltd
1.02M
6.58%
--
--
Mar 21, 2025
VR Adviser, LLC
987.26K
6.37%
--
--
Mar 31, 2025
IDG Capital Partners
915.85K
5.91%
+61.97K
+7.26%
Dec 30, 2024
Wealth Strategy Holding Ltd
908.79K
5.87%
--
--
Mar 21, 2025
Woodline Partners LP
164.37K
1.06%
+64.67K
+64.88%
Mar 31, 2025
Wellington Shields Capital Management, LLC
90.89K
0.59%
+5.06K
+5.89%
Mar 31, 2025
Adar1 Capital Management LLC
47.42K
0.31%
+1.10K
+2.37%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
Datum
Art
Verhältnis
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
